Title of article :
Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy: Weiss C, Wittlinger M, Engehausen DG, Krause FS, Ott OJ, Dunst J, Sauer R, Rِdel C, Department of Radiation Therapy, University of Erlangen, E
Author/Authors :
Speight، نويسنده , , Joycelyn L. Speight، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Pages :
2
From page :
447
To page :
448
Abstract :
Purpose rd treatment for superficial bladder cancer is transurethral resection of the bladder tumor (TURBT) followed by intravesical therapy. Little is known about the biologic behavior and treatment response of superficial disease within an irradiated bladder. We specifically analyzed patients who developed superficial recurrence after TURBT and radiotherapy or radiochemotherapy. ts and Methods n 1982 and 2006, a total of 531 consecutive patients with invasive bladder cancer were treated by using various bladder-sparing protocols at our institution. Of these, 389 (76%) achieved a complete response after TURBT and radiotherapy/radiochemotherapy. During follow-up, 68 of 389 patients (17%) developed a superficial local relapse (≤T1) and form the subject of this study. s four of 68 patients underwent conservative TURBT with or without intravesical treatment (4 patients underwent immediate cystectomy): 31 of 64 patients (48%) had no further bladder recurrence, 21 (33%) experienced additional superficial recurrences, and 12 (19%) ultimately progressed to muscle-invasive disease. Disease-specific survival rates were 87% and 72% at 5 and 10 years, respectively. Compared with 255 patients without local bladder relapse after primary treatment, no significant difference was found for disease-specific survival rates (72% after superficial vs. 79% without local relapse at 10 years, P = 0.78). However, significantly fewer patients with a superficial relapse survived with their native bladder (50% after superficial vs. 76% without local relapse at 10 years, P < 0.001). sion her bladder-sparing approach with TURBT and intravesical therapy is reasonable for patients with superficial relapse after combined-modality treatment without compromising survival. However, these patients are at greater risk of requiring late cystectomy.
Journal title :
Urologic Oncology
Serial Year :
2008
Journal title :
Urologic Oncology
Record number :
1888915
Link To Document :
بازگشت